Novartis’ remibrutinib shows promising results in Phase III studies for chronic spontaneous urticaria

Novartis has revealed encouraging data from the Phase III REMIX-1 and REMIX-2 studies. The studies focused on remibrutinib, a highly selective, oral Bruton’s tyrosine kinase ... Read More